Android app on Google Play

Piper Jaffray Reiterates Underweight Rating on Seattle Genetics (SGEN)

December 9, 2013 9:38 AM EST Send to a Friend
Get Alerts SGEN Hot Sheet
Price: $38.99 +0.39%

Rating Summary:
    6 Buy, 4 Hold, 11 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 14 | New: 11
Trade SGEN Now!
Join SI Premium – FREE
Piper Jaffray maintained an Underweight rating on Seattle Genetics (NASDAQ: SGEN) with a price target of $26.00. Analyst Edward Tenthoff thinks Adcetris' safety
profile is worrisome. Tenthoff pointed to severe toxicities associated with Adcetris and made note to 86 deaths reported with the FDA between February 1 and October 31. 46 of these deaths could be due to Adcetris, 21 were unknown, and 19 were unlikely.

For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.

Shares of Seattle Genetics closed at $44.35 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray


Show me the data
Terry Ramsey on 2013-12-09 13:31:31
Mark as Spam | Reply to this comment

Edward Tenthoff should divulge the source of the data he is reporting ... specifically "46 of these deaths could be due to Adcetris."
Is he starting an unscrupulous, malicious rumor?

Add Your Comment